Tyrosine Kinase Inhibitors: all 10,744 studies that test it

Page 105 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.

• Treatment of Lung Adenocarcinoma With Bronchioloalveolar FeatureCompletedNCT00198380Phase 2
• A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFRTerminatedNCT00198159Phase 2
• Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck CancerTerminatedNCT00195078Phase 1/2
• Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary SiteCompletedNCT00193622Phase 2
• Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung CancerCompletedNCT00193336Phase 2
• Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck CancerCompletedNCT00193284Phase 2
• OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell CarcinomaCompletedNCT00193154Phase 2
• Gemcitabine With Curcumin for Pancreatic CancerCompletedNCT00192842Phase 2
• A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based TherapyCompletedNCT00189358Phase 2
• Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLCCompletedNCT00188617Phase 2
• Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and NeckCompletedNCT00185835Phase 1
• Study of Xeloda and Gleevec in Patients With Advanced Solid TumorsCompletedNCT00183833Phase 1
• Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian CancerCompletedNCT00181688Phase 2
• Pharmacokinetics of Curcumin in Healthy VolunteersCompletedNCT00181662Not applicable
• Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and NeckStatus unknownNCT00180921Phase 2
• Glivec Phase II Pediatric StudyTerminatedNCT00180830Phase 2
• Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic CarcinomaCompletedNCT00177242Phase 2
• Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast CancerCompletedNCT00174434Phase 1
• PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC PatientsCompletedNCT00174356Phase 1
• Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung CancerCompletedNCT00173875Phase 2
• Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)CompletedNCT00171977Phase 4
• Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)TerminatedNCT00171938Phase 2
• Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
• Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)CompletedNCT00171899Phase 4
• A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic SyndromeTerminatedNCT00171860Phase 2
• Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced CancerCompletedNCT00171587Phase 1/2
• Rollover Study Of Lapatinib In Cancer PatientsCompletedNCT00169533Phase 1
• Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract CarcinomasTerminatedNCT00169221Phase 2
• Protein Tyrosine Kinases (PTK) in Multiple MyelomaCompletedNCT00165347Phase 2
• A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's DiseaseCompletedNCT00164749Phase 1/2
• A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung CancerCompletedNCT00162318Phase 1
• Study of Dasatinib in Patients With Advanced Solid TumorsTerminatedNCT00162214Phase 1
• Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.CompletedNCT00160043Phase 2
• Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.WithdrawnNCT00159016Phase 2
• Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer PatientsCompletedNCT00158782Phase 1
• Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLCCompletedNCT00156286Phase 2
• Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
• Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic LeukemiaCompletedNCT00154349Phase 2
• A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.CompletedNCT00154336Phase 2
• Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)CompletedNCT00150202Phase 3
• Efficacy and Safety of Imatinib in ChordomaCompletedNCT00150072Phase 2
• Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.Status unknownNCT00149136Phase 2
• Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone TherapyCompletedNCT00148772Phase 2
• AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One YearStatus unknownNCT00146913Phase 2
• Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid CarcinomaCompletedNCT00144976Not applicable
• A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic FunctionCompletedNCT00139620Phase 1
• Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT00138632Phase 1/2
• Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated MesotheliomaCompletedNCT00137826Phase 2
• Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer PatientsCompletedNCT00137800Phase 2
• Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic CancerCompletedNCT00137761Phase 2
• A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)CompletedNCT00136409Phase 2
• Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)CompletedNCT00135005Phase 1
• Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)TerminatedNCT00134667Phase 4
• Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate CancerCompletedNCT00134355Phase 2
• Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal CancerCompletedNCT00134069Phase 1
• Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00131989Phase 1
• Gleevec Idiopathic Pulmonary Fibrosis (IPF) StudyCompletedNCT00131274Phase 2/3
• Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous LeukemiaCompletedNCT00130702Phase 2
• Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)CompletedNCT00130195Phase 2
• Study of XL820 in Adults With Solid TumorsCompletedNCT00129571Phase 1
• Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00128700Phase 1/2
• Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or MetastaticCompletedNCT00127829Phase 1
• Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00126620Phase 1
• Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT00126542Phase 2
• Tarceva and Capecitabine for Pancreatic CancerCompletedNCT00125021Phase 2
• Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal CancerCompletedNCT00123851Phase 2
• Imatinib in Dermatofibrosarcoma Protuberans (DFSP)CompletedNCT00122473Phase 1/2
• A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic MelanomaCompletedNCT00121680Phase 1
• A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid CancerCompletedNCT00121628Phase 2
• 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00121264Phase 1
• Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006CompletedNCT00119639Phase 1
• Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00119249Phase 2
• Study of Oral AEE788 in Adults With Advanced CancerCompletedNCT00118456Phase 1
• Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal CancerCompletedNCT00118261Phase 1
• Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionCompletedNCT00118170Phase 1
• PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to ImatinibCompletedNCT00117299Phase 2
• Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)CompletedNCT00116935Phase 3
• Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal CancerCompletedNCT00116506Phase 2
• Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)CompletedNCT00116376Phase 1/2
• Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck CancerCompletedNCT00114283Phase 2
• Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT00113347Phase 1
• BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib MesylateStatus unknownNCT00112775Phase 2
• Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal TumorCompletedNCT00112632Phase 2
• Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast CancerCompletedNCT00111787Phase 2
• Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell CarcinomaCompletedNCT00111020Phase 3
• Research Study for Patients With Metastatic Renal Cell CarcinomaTerminatedNCT00110344Phase 2
• A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following ChemotherapyCompletedNCT00109265Phase 2
• Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.CompletedNCT00107432Phase 2
• AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma MultiformeCompletedNCT00107237Phase 1/2
• GW572016 to Treat Recurrent Malignant Brain TumorsCompletedNCT00107003Phase 2
• Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast CancerCompletedNCT00105950Phase 2
• Study of XL999 in Adults With Solid TumorsCompletedNCT00104117Phase 1
• BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT00103701Phase 1
• S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach CancerCompletedNCT00103324Phase 2
• Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal TumorCompletedNCT00103168Phase 3
• Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung CancerCompletedNCT00103051Phase 2
• A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast CancerTerminatedNCT00102895Phase 2
• Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT00101595Phase 2
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
• Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00101114Phase 2

← Tyrosine Kinase Inhibitors overview